Takeda Pharmaceutical Co Ltd (TAK) KPIs and segments
Close on Nov 18, 2026Market cap $73.30BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Takeda Pharmaceutical · năm tài chính kết thúc ngày 31 tháng 3
Nhìn nhanh KPI của Takeda Pharmaceutical: 108 chỉ số vận hành, trong đó có Gastroenterology Business Area Total Revenue, Rare Diseases Business Area Total Revenue và Plasma-Derived Therapies Immunology Business Area, lấy từ 92 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Takeda Pharmaceutical kết thúc ngày 31 tháng 3 — Q2 FY27 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gastroenterology (GI) Business Area Total Revenue15 | 390.70 | 386.10 | 328.80 | 385.80 | 353.50 | 339.30 | 317.70 | 344.10 | 346.70 | 348.50 | 280.20 | 339.20 | |
Gastroenterology (GI) Business Area Total Revenue — U.S. Revenue1 | 220.10 | 210.30 | 167.10 | 216.90 | 198.90 | 193.50 | 178.30 | 193.10 | 202.40 | 203.20 | 148.10 | 199.30 | |
Gastroenterology (GI) Business Area Total Revenue — Japan Revenue1 | 34.60 | 36.40 | 30.80 | 37.90 | 32.70 | 34.60 | 29.30 | 34.80 | 31.00 | 32.20 | 27.80 | 32.90 | |
Gastroenterology (GI) Business Area Total Revenue — Europe and Canada Revenue1 | 77.20 | 79.50 | 87.40 | 88.10 | 81.30 | 74.00 | 75.90 | 75.60 | 74.80 | 74.10 | 71.00 | 72.10 | |
Gastroenterology (GI) Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 50.40 | 52.60 | 36.40 | 36.20 | 33.80 | 31.60 | 28.60 | 33.90 | 32.60 | 32.80 | 27.30 | 28.40 | |
Gastroenterology (GI) Business Area Total Revenue — International (Ex-U.S.) Revenue1 | 8.50 | 7.30 | 7.20 | 6.70 | 6.70 | 5.60 | 5.50 | 6.70 | 5.90 | 6.10 | 6.00 | 6.60 | |
Gastroenterology (GI) Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 10.50 | 13.80 | 3.50 | 12.10 | 2.00 | -2.60 | 13.40 | 1.40 | 14.30 | 18.70 | 18.20 | 9.00 | |
Gastroenterology (GI) Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | 1.90 | 3.10 | -2.00 | 7.50 | 3.70 | 2.60 | 10.80 | 1.90 | 9.20 | 6.00 | 8.60 | 4.60 | |
ENTYVIO (Vedolizumab — Ulcerative Colitis & Crohn's Disease)7 | 273.40 | 268.30 | 213.50 | 265.30 | 246.70 | 232.50 | 215.10 | 225.80 | 238.90 | 234.40 | 181.60 | 227.60 | |
GATTEX / REVESTIVE (Teduglutide — Short Bowel Syndrome)7 | 38.50 | 41.40 | 35.90 | 38.10 | 36.80 | 34.80 | 32.90 | 40.10 | 36.40 | 36.80 | 29.30 | 31.10 | |
TAKECAB / VOCINTI (Vonoprazan — Acid-Related Diseases)7 | 38.70 | 37.40 | 35.30 | 39.50 | 33.90 | 35.00 | 31.80 | 34.70 | 31.10 | 33.20 | 28.20 | 31.50 | |
DEXILANT (Dexlansoprazole — GERD)7 | 9.50 | 8.80 | 11.90 | 9.00 | 8.00 | 8.30 | 9.50 | 9.20 | 8.00 | 11.90 | 9.20 | 13.00 | |
PANTOLOC / CONTROLOC (Pantoprazole)7 | 9.80 | 10.20 | 12.00 | 11.30 | 10.90 | 10.30 | 11.50 | 10.50 | 11.60 | 10.90 | 11.00 | 12.60 | |
LIALDA / MEZAVANT (Mesalamine — Ulcerative Colitis)5 | 8.80 | 7.90 | 7.50 | 7.80 | 7.50 | 6.30 | 5.90 | 8.00 | 6.80 | 6.60 | 7.40 | 8.20 | |
EOHILIA (Budesonide Oral Suspension — Eosinophilic Esophagitis)7 | 2.10 | 2.30 | 1.90 | 2.60 | 2.20 | 2.00 | 1.50 | 1.70 | 1.30 | 0.90 | 0.20 | 0.00 | |
Other Gastroenterology Products6 | 9.90 | 9.80 | 11.00 | 12.20 | 7.40 | 10.00 | 7.00 | 8.50 | 6.80 | 8.20 | 8.00 | 9.70 | |
Rare Diseases Business Area Total Revenue17 | 189.70 | 206.00 | 188.20 | 194.00 | 184.10 | 196.40 | 173.80 | 190.40 | 189.20 | 199.50 | 164.10 | 183.40 | |
Rare Diseases Business Area Total Revenue — U.S. Revenue1 | 77.20 | 82.60 | 75.40 | 87.90 | 84.30 | 82.30 | 81.50 | 90.50 | 87.00 | 89.80 | 80.30 | 93.00 | |
Rare Diseases Business Area Total Revenue — Japan Revenue1 | 9.80 | 10.50 | 9.20 | 11.30 | 10.50 | 10.40 | 8.90 | 10.60 | 9.40 | 10.10 | 8.00 | 10.20 | |
Rare Diseases Business Area Total Revenue — Europe and Canada Revenue1 | 52.80 | 53.10 | 57.80 | 56.40 | 52.30 | 53.40 | 53.10 | 52.20 | 52.50 | 54.50 | 54.80 | 57.80 | |
Rare Diseases Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 49.80 | 59.80 | 45.80 | 38.40 | 37.00 | 50.30 | 30.30 | 37.10 | 40.20 | 45.10 | 42.50 | 43.10 | |
Rare Diseases Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 3.00 | 4.90 | 8.30 | 1.90 | -2.70 | -1.60 | 5.90 | 3.80 | 11.20 | 16.80 | 9.30 | 6.70 | |
Rare Diseases Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | -5.40 | -5.80 | 1.00 | -3.40 | -1.70 | 3.00 | 3.70 | 4.00 | 6.20 | 4.40 | 6.60 | 6.10 | |
TAKHZYRO (Lanadelumab — Hereditary Angioedema Prophylaxis)7 | 55.70 | 59.90 | 53.30 | 57.40 | 58.20 | 55.10 | 55.10 | 57.00 | 55.00 | 56.00 | 42.20 | 49.30 | |
ADVATE (Antihemophilic Factor Recombinant — Hemophilia A)7 | 24.80 | 25.80 | 26.20 | 25.70 | 25.60 | 28.00 | 24.90 | 28.10 | 26.90 | 31.90 | 29.00 | 31.20 | |
ADYNOVATE / ADYNOVI (PEGylated Recombinant Factor VIII — Hemophilia A)6 | 13.00 | 13.80 | 13.00 | 14.90 | 14.70 | 14.10 | 14.30 | 15.90 | 16.90 | 17.60 | 15.10 | 17.80 | |
ELAPRASE (Idursulfase — Hunter Syndrome / MPS II)7 | 23.30 | 27.70 | 26.30 | 25.10 | 21.00 | 28.00 | 20.10 | 24.00 | 25.10 | 28.00 | 21.60 | 24.30 | |
REPLAGAL (Agalsidase Alfa — Fabry Disease)7 | 19.50 | 21.70 | 21.60 | 20.20 | 18.50 | 20.20 | 17.60 | 18.90 | 19.90 | 21.40 | 18.50 | 18.90 | |
VPRIV (Velaglucerase Alfa — Type 1 Gaucher Disease)7 | 14.30 | 16.80 | 14.40 | 14.50 | 13.10 | 15.30 | 12.20 | 14.30 | 13.30 | 13.70 | 12.30 | 14.60 | |
LIVTENCITY (Maribavir — Post-Transplant Refractory CMV)7 | 14.70 | 14.10 | 12.00 | 12.80 | 11.60 | 10.50 | 8.50 | 9.00 | 7.90 | 7.60 | 5.10 | 5.60 | |
VONVENDI (von Willebrand Factor Recombinant)7 | 8.30 | 7.60 | 7.00 | 6.90 | 5.90 | 5.50 | 5.50 | 5.10 | 5.10 | 5.30 | 4.20 | 4.60 | |
ADZYNMA (ADAMTS13, Recombinant-krhn — Congenital TTP)7 | 4.80 | 4.10 | 3.60 | 3.50 | 2.40 | 2.40 | 2.30 | 2.30 | 1.40 | 1.10 | 0.40 | 0.00 | |
FIRAZYR (Icatibant — Acute Hereditary Angioedema)7 | 3.70 | 3.50 | 2.90 | 4.50 | 4.10 | 4.50 | 4.00 | 4.30 | 4.80 | 5.00 | 4.00 | 5.50 | |
Other Rare Diseases Products6 | 7.70 | 11.10 | 8.00 | 8.50 | 9.00 | 12.80 | 9.30 | 11.50 | 13.00 | 11.90 | 8.60 | 8.60 | |
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue13 | 277.20 | 283.90 | 267.00 | 273.10 | 256.60 | 260.90 | 248.50 | 248.50 | 264.20 | 271.40 | 229.20 | 244.30 | |
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — U.S. Revenue1 | 165.80 | 170.50 | 152.60 | 169.60 | 159.90 | 163.70 | 151.30 | 156.50 | 163.70 | 172.70 | 123.00 | 147.20 | |
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — Japan Revenue1 | 0.10 | 0.10 | 0.00 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | |||
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — Europe and Canada Revenue1 | 4.00 | 4.90 | 4.60 | 4.50 | 3.30 | 3.80 | 2.90 | 4.00 | 5.20 | 5.60 | |||
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 6.90 | 9.10 | 9.40 | 5.80 | 7.40 | 11.20 | 5.70 | 8.80 | 8.10 | 14.50 | |||
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — International (Ex-U.S.) Revenue1 | 100.50 | 99.40 | 100.40 | 93.00 | 85.90 | 82.10 | 88.50 | 79.10 | 87.10 | 78.60 | 84.30 | 75.60 | |
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 8.10 | 8.80 | 7.50 | 9.90 | -2.90 | -3.90 | 8.40 | 1.70 | 19.60 | 29.70 | 17.80 | 18.30 | |
Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | -0.90 | -2.10 | 1.80 | 5.00 | -0.80 | 1.70 | 4.80 | 1.90 | 14.00 | 14.70 | 9.40 | 14.40 | |
Immunoglobulin Portfolio (GAMMAGARD LIQUID, HYQVIA, CUVITRU)4 | 209.90 | 213.90 | 196.90 | 206.60 | 193.00 | 194.00 | 181.70 | 185.00 | 189.60 | 201.50 | 158.90 | 176.50 | |
Albumin Portfolio (FLEXBUMIN, HUMAN ALBUMIN)4 | 34.50 | 34.60 | 38.70 | 35.50 | 33.90 | 32.20 | 40.10 | 30.90 | 40.90 | 29.40 | 39.70 | 35.30 | |
FEIBA (Anti-Inhibitor Coagulant Complex)7 | 8.60 | 9.10 | 7.70 | 7.70 | 7.70 | 9.70 | 6.50 | 9.20 | 9.70 | 13.90 | 11.60 | 9.10 | |
CINRYZE (C1 Esterase Inhibitor — Human)7 | 3.10 | 3.40 | 2.80 | 3.30 | 3.40 | 3.80 | 3.60 | 4.60 | 3.90 | 4.30 | 3.70 | 5.00 | |
HEMOFIL / IMMUNATE / IMMUNINE (Plasma-Derived Coagulation Factors)7 | 5.60 | 6.90 | 7.70 | 5.10 | 5.00 | 7.60 | 4.20 | 6.80 | 5.80 | 8.70 | 5.00 | 5.20 | |
Other Plasma-Derived Therapies (PDT) Products4 | 15.60 | 16.10 | 13.10 | 14.90 | 13.40 | 13.50 | 12.20 | 12.00 | 14.30 | 13.60 | 10.30 | 13.10 | |
Oncology Business Area Total Revenue17 | 151.40 | 165.60 | 143.50 | 148.80 | 149.10 | 138.80 | 132.00 | 143.40 | 142.90 | 142.10 | 116.10 | 121.10 | |
Oncology Business Area Total Revenue — U.S. Revenue1 | 48.70 | 50.20 | 46.90 | 51.40 | 48.50 | 41.60 | 44.40 | 52.50 | 49.80 | 51.80 | 39.50 | 38.10 | |
Oncology Business Area Total Revenue — Japan Revenue1 | 22.50 | 23.20 | 21.10 | 28.00 | 26.00 | 26.10 | 23.50 | 26.70 | 24.10 | 24.60 | 21.20 | 25.70 | |
Oncology Business Area Total Revenue — Europe and Canada Revenue1 | 34.50 | 37.00 | 35.80 | 34.10 | 33.60 | 30.60 | 28.80 | 28.20 | 33.70 | 28.80 | 26.50 | 26.70 | |
Oncology Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 43.00 | 52.60 | 36.90 | 32.60 | 38.40 | 38.30 | 33.30 | 33.70 | 33.30 | 35.00 | 27.80 | 28.50 | |
Oncology Business Area Total Revenue — International (Ex-U.S.) Revenue1 | 2.70 | 2.60 | 2.80 | 2.70 | 2.50 | 2.10 | 2.10 | 2.30 | 2.00 | 2.00 | 1.10 | 2.00 | |
Oncology Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 1.50 | 19.40 | 8.70 | 3.80 | 4.30 | -2.30 | 13.70 | 18.40 | 24.60 | 28.60 | 23.80 | 1.20 | |
Oncology Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | -5.90 | 8.20 | 2.00 | -0.90 | 5.00 | 1.80 | 12.70 | 18.80 | 20.20 | 17.20 | 19.70 | -0.80 | |
LEUPLIN / ENANTONE (Leuprorelin — Prostate & Breast Cancer, Endometriosis)7 | 32.20 | 31.70 | 30.50 | 31.60 | 31.30 | 27.30 | 30.10 | 28.70 | 31.00 | 29.40 | 27.70 | 30.90 | |
ADCETRIS (Brentuximab Vedotin — CD30+ Lymphomas)6 | 37.00 | 48.50 | 33.40 | 32.20 | 37.30 | 37.20 | 29.40 | 31.40 | 33.70 | 34.50 | 25.20 | 30.00 | |
NINLARO (Ixazomib — Oral Proteasome Inhibitor for Multiple Myeloma)7 | 20.20 | 24.00 | 21.10 | 19.50 | 20.60 | 20.90 | 19.80 | 24.00 | 23.50 | 23.90 | 20.60 | 20.40 | |
ICLUSIG (Ponatinib — CML & Ph+ ALL)5 | 18.40 | 18.70 | 19.40 | 21.10 | 18.60 | 15.90 | 15.90 | 19.40 | 18.60 | 16.80 | 13.20 | 14.40 | |
FRUZAQLA (Fruquintinib — Refractory Metastatic Colorectal Cancer)7 | 16.20 | 17.10 | 12.20 | 15.70 | 14.90 | 12.30 | 11.90 | 13.00 | 11.10 | 11.90 | 7.80 | 2.20 | |
ALUNBRIG (Brigatinib — ALK+ Non-Small Cell Lung Cancer)7 | 9.90 | 9.70 | 10.00 | 9.20 | 9.60 | 8.20 | 8.90 | 9.30 | 8.80 | 9.40 | 7.40 | 7.40 | |
VECTIBIX (Panitumumab — Colorectal Cancer, Japan)7 | 5.10 | 5.00 | 5.50 | 7.30 | 6.70 | 6.90 | 5.50 | 7.30 | 6.90 | 6.60 | 5.90 | 6.90 | |
ZEJULA (Niraparib — Ovarian Cancer, Japan)7 | 3.50 | 3.70 | 3.30 | 3.70 | 3.50 | 3.70 | 3.30 | 3.80 | 3.50 | 3.70 | 3.10 | 3.70 | |
CABOMETYX (Cabozantinib — Renal & Hepatocellular Carcinoma, Japan)7 | 2.10 | 2.20 | 1.60 | 2.20 | 2.00 | 2.30 | 1.70 | 2.20 | 2.10 | 2.30 | 1.90 | 2.30 | |
Other Oncology Products6 | 6.80 | 5.00 | 6.40 | 6.20 | 4.50 | 4.00 | 5.50 | 4.20 | 3.60 | 3.60 | 3.30 | 2.90 | |
Vaccines Business Area Total Revenue8 | 22.70 | 14.00 | 4.60 | 23.30 | 20.20 | 11.50 | 5.50 | 11.80 | 25.60 | 12.50 | 20.80 | 11.70 | |
Vaccines Business Area Total Revenue — U.S. Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
Vaccines Business Area Total Revenue — Japan Revenue | 7.50 | 2.50 | 1.60 | 6.70 | 7.90 | 2.70 | -0.10 | 1.70 | 15.20 | 3.00 | |||
Vaccines Business Area Total Revenue — Europe and Canada Revenue1 | 1.50 | 1.00 | 1.30 | 1.10 | 0.90 | 0.80 | 0.90 | 1.30 | 1.10 | 1.20 | |||
Vaccines Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 13.70 | 10.40 | 1.70 | 15.60 | 11.40 | 7.90 | 4.70 | 8.80 | 9.20 | 8.30 | |||
Vaccines Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 12.30 | 21.80 | -16.40 | 98.10 | -21.10 | -8.40 | -73.50 | 0.70 | 252.00 | 18.70 | |||
Vaccines Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | 6.40 | 10.10 | -20.90 | 88.10 | -21.90 | -6.20 | -73.70 | 0.90 | 248.00 | 9.70 | |||
QDENGA (Dengue Tetravalent Vaccine — TAK-003)7 | 15.20 | 11.50 | 3.00 | 16.70 | 12.30 | 8.80 | 5.60 | 10.10 | 10.40 | 9.50 | 3.80 | 3.80 | |
Other Vaccine Products (Pandemic, Seasonal Influenza & Partnered Vaccines)4 | 7.50 | 2.50 | 1.60 | 6.70 | 7.90 | 2.70 | -0.10 | 1.70 | 15.20 | 3.00 | 17.10 | 7.90 | |
Neuroscience Business Area Total Revenue11 | 107.30 | 113.60 | 99.80 | 108.40 | 97.50 | 108.60 | 109.30 | 141.90 | 145.50 | 169.10 | 152.10 | 144.20 | |
Neuroscience Business Area Total Revenue — U.S. Revenue1 | 46.90 | 51.90 | 44.70 | 53.90 | 50.40 | 63.90 | 67.70 | 96.30 | 99.90 | 112.10 | 108.30 | 94.60 | |
Neuroscience Business Area Total Revenue — Japan Revenue1 | 16.20 | 17.20 | 13.90 | 17.00 | 14.40 | 15.00 | 12.20 | 14.40 | 12.60 | 13.30 | 11.10 | 12.90 | |
Neuroscience Business Area Total Revenue — Europe and Canada Revenue1 | 32.00 | 32.00 | 35.00 | 32.10 | 28.00 | 25.50 | 26.00 | 27.70 | 27.00 | 33.40 | 28.50 | 30.40 | |
Neuroscience Business Area Total Revenue — Growth and Emerging Markets Revenue1 | 12.10 | 12.50 | 6.30 | 5.40 | 4.70 | 4.20 | 3.50 | 3.60 | 6.00 | 10.20 | 4.20 | 6.20 | |
Neuroscience Business Area Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | 10.10 | 4.60 | -8.70 | -23.60 | -33.00 | -35.70 | -28.10 | -1.60 | -5.30 | -4.50 | -5.20 | -17.50 | |
Neuroscience Business Area Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | 2.00 | -4.80 | -13.80 | -26.80 | -31.50 | -32.60 | -30.20 | -1.20 | -9.30 | -15.00 | -13.60 | -21.30 | |
VYVANSE / ELVANSE (Lisdexamfetamine Dimesylate — ADHD & BED)7 | 51.50 | 54.10 | 48.10 | 48.60 | 48.70 | 57.90 | 63.00 | 84.40 | 88.50 | 114.60 | 110.30 | 86.60 | |
TRINTELLIX (Vortioxetine — Major Depressive Disorder)7 | 34.30 | 37.00 | 30.50 | 34.40 | 28.90 | 28.10 | 27.60 | 34.00 | 33.10 | 31.00 | 24.60 | 29.30 | |
ADDERALL XR (Mixed Amphetamine Salts Extended-Release — ADHD)7 | 5.30 | 5.10 | 6.40 | 7.80 | 4.50 | 6.10 | 4.50 | 7.10 | 9.10 | 7.70 | 6.50 | 12.60 | |
INTUNIV (Guanfacine Extended-Release — ADHD)7 | 12.00 | 12.70 | 10.70 | 12.50 | 11.40 | 11.70 | 9.60 | 10.90 | 9.60 | 10.20 | 8.10 | 9.20 | |
Other Neuroscience Products5 | 4.20 | 4.70 | 4.20 | 5.10 | 4.10 | 4.90 | 4.50 | 5.50 | 5.20 | 5.50 | 2.60 | 6.50 | |
Other Business Areas & Established Products Total Revenue4 | 48.10 | 50.70 | 62.60 | 58.30 | 51.90 | 51.20 | 66.50 | 64.00 | 61.90 | 64.90 | 88.30 | 67.30 | |
Other Business Areas & Established Products Total Revenue — Total Revenue YoY Change (Actual Exchange Rate / AER %) | -7.20 | -1.10 | -5.90 | -9.00 | -16.20 | -21.10 | -24.70 | -4.80 | -15.30 | -25.30 | -7.90 | -28.20 | |
Other Business Areas & Established Products Total Revenue — Total Revenue YoY Change (Constant Exchange Rate / CER %) | -13.60 | -11.80 | -11.40 | -14.90 | -17.00 | -18.00 | -25.90 | -3.30 | -17.60 | -31.10 | 12.50 | -38.90 | |
AZILVA (Azilsartan — Hypertension, Japan)7 | 0.80 | 0.90 | 2.80 | 1.80 | 1.00 | 1.50 | 3.00 | 2.90 | 2.60 | 3.20 | 4.60 | 5.40 | |
FOSRENOL (Lanthanum Carbonate — Hyperphosphatemia)5 | 2.00 | 1.60 | 2.10 | 1.90 | 2.30 | 2.50 | 2.00 | 2.00 | 2.20 | 1.80 | 2.40 | 3.00 | |
Total Consolidated Revenue (Regional Summary)6 | 1,187.10 | 1,219.90 | 1,094.50 | 1,191.70 | 1,112.80 | 1,106.70 | 1,053.40 | 1,144.10 | 1,176.00 | 1,208.00 | 1,050.90 | 1,111.20 | |
Total Consolidated Revenue (Regional Summary) — YoY Change (Actual Exchange Rate / AER %) | 6.70 | 10.20 | 3.90 | 4.20 | -5.40 | -8.40 | 0.20 | 3.00 | 12.70 | 14.10 | 9.90 | 1.30 | |
United States Revenue2 | 561.80 | 568.90 | 490.70 | 582.20 | 545.20 | 546.70 | 538.20 | 593.90 | 610.90 | 636.70 | 510.20 | 580.70 | |
United States Revenue — Share of Consolidated Revenue (%) | 47.30 | 46.60 | 44.80 | 48.90 | 49.00 | 49.40 | 51.10 | 51.90 | 51.90 | 52.70 | 48.60 | 52.30 | |
United States Revenue — YoY Change (Actual Exchange Rate / AER %) | 3.00 | 4.10 | -8.80 | -2.00 | -10.80 | -14.10 | 5.50 | 2.30 | 11.00 | 14.80 | 5.90 | -1.40 | |
Japan Revenue2 | 110.00 | 103.90 | 93.70 | 120.40 | 111.10 | 108.00 | 93.70 | 108.40 | 113.40 | 102.90 | 108.70 | 114.10 | |
Japan Revenue — Share of Consolidated Revenue (%) | 9.30 | 8.50 | 8.60 | 10.10 | 10.00 | 9.80 | 8.90 | 9.50 | 9.60 | 8.50 | 10.30 | 10.30 | |
Japan Revenue — YoY Change (Actual Exchange Rate / AER %) | -1.00 | -3.80 | -0.10 | 11.10 | -2.10 | 4.90 | -13.80 | -5.00 | 9.40 | -17.50 | -11.00 | -11.20 | |
Europe and Canada (EUCAN) Revenue4 | 277.80 | 282.10 | 283.50 | 267.20 | 245.20 | 236.90 | 259.70 | 262.60 | 263.20 | 269.80 | 245.30 | 261.60 | |
Europe and Canada (EUCAN) Revenue — Share of Consolidated Revenue (%) | 23.40 | 23.10 | 25.90 | 22.40 | 22.00 | 21.40 | 24.70 | 22.90 | 22.40 | 22.30 | 23.30 | 23.50 | |
Europe and Canada (EUCAN) Revenue — YoY Change (Actual Exchange Rate / AER %) | 13.30 | 19.10 | 20.80 | 13.30 | 3.70 | -2.80 | 5.90 | 0.40 | 11.70 | 20.30 | 16.70 | 17.10 | |
Of Which: Europe Revenue1 | 277.80 | 282.10 | 283.50 | 267.20 | 245.20 | 236.90 | |||||||
Of Which: Europe Revenue — Share of Consolidated Revenue (%) | 23.40 | 23.10 | 25.90 | 22.40 | 22.00 | 21.40 | |||||||
Of Which: Canada & Other EUCAN Revenue1 | 237.50 | 265.10 | 226.60 | 221.90 | 211.30 | 215.10 | |||||||
Of Which: Canada & Other EUCAN Revenue — Share of Consolidated Revenue (%) | 20.00 | 21.70 | 20.70 | 18.60 | 19.00 | 19.40 | |||||||
Growth and Emerging Markets (Other) Revenue7 | 237.50 | 265.10 | 226.60 | 221.90 | 211.30 | 215.10 | 161.70 | 179.30 | 188.50 | 198.60 | 186.60 | 154.80 | |
Growth and Emerging Markets (Other) Revenue — Share of Consolidated Revenue (%) | 20.00 | 21.70 | 20.70 | 18.60 | 19.00 | 19.40 | 15.40 | 15.70 | 16.00 | 16.40 | 17.80 | 13.90 | |
Growth and Emerging Markets (Other) Revenue — YoY Change (Actual Exchange Rate / AER %) | 12.40 | 23.20 | 21.50 | 6.90 | -2.60 | -4.50 | -13.30 | 15.90 | 22.90 | 28.10 | 31.70 | -0.40 | |
Of Which: China Revenue2 | 53.90 | 52.30 | 54.00 | 48.40 | 49.40 | 43.20 | 57.90 | 43.70 | 52.00 | 38.20 | 51.80 | 43.80 | |
Of Which: China Revenue — Share of Consolidated Revenue (%) | 4.50 | 4.30 | 4.90 | 4.10 | 4.40 | 3.90 | 5.50 | 3.80 | 4.40 | 3.20 | 4.90 | 3.90 | |
Of Which: China Revenue — YoY Change (Actual Exchange Rate / AER %) | 9.00 | 21.00 | -6.70 | 11.00 | -4.90 | 13.20 | 11.70 | -0.30 | 30.00 | -4.20 | |||
Of Which: Asia (Excluding Japan & China) Revenue2 | 28.00 | 26.60 | 25.70 | 25.10 | 24.80 | 23.00 | 24.00 | 25.50 | 24.10 | 25.70 | 20.60 | 21.70 | |
Of Which: Asia (Excluding Japan & China) Revenue — Share of Consolidated Revenue (%) | 2.40 | 2.20 | 2.40 | 2.10 | 2.20 | 2.10 | 2.30 | 2.20 | 2.10 | 2.10 | 2.00 | 2.00 | |
Of Which: Asia (Excluding Japan & China) Revenue — YoY Change (Actual Exchange Rate / AER %) | 12.90 | 15.40 | 7.20 | -1.60 | 2.70 | -10.50 | 16.60 | 17.50 | 4.50 | 22.70 | |||
Of Which: Latin America Revenue2 | 70.30 | 74.20 | 62.80 | 72.90 | 60.90 | 57.60 | 44.60 | 58.70 | 60.30 | 72.20 | 59.70 | 46.30 | |
Of Which: Latin America Revenue — Share of Consolidated Revenue (%) | 5.90 | 6.10 | 5.70 | 6.10 | 5.50 | 5.20 | 4.20 | 5.10 | 5.10 | 6.00 | 5.70 | 4.20 | |
Of Which: Latin America Revenue — YoY Change (Actual Exchange Rate / AER %) | 15.40 | 28.90 | 40.60 | 24.10 | 1.00 | -20.30 | -25.30 | 26.70 | 24.80 | 65.20 | 53.30 | 21.30 | |
Of Which: Russia / CIS Revenue2 | 17.40 | 35.40 | 19.20 | 17.30 | 14.30 | 28.90 | 10.40 | 19.00 | 19.20 | 23.70 | 27.20 | 14.30 | |
Of Which: Russia / CIS Revenue — Share of Consolidated Revenue (%) | 1.50 | 2.90 | 1.80 | 1.50 | 1.30 | 2.60 | 1.00 | 1.70 | 1.60 | 2.00 | 2.60 | 1.30 | |
Of Which: Russia / CIS Revenue — YoY Change (Actual Exchange Rate / AER %) | 22.20 | 22.20 | 84.20 | -8.70 | -25.80 | 21.90 | -61.80 | 33.10 | 40.00 | 36.70 | 25.30 | -50.60 | |
Of Which: Middle East, Oceania & Africa (Other GEM) Revenue2 | 67.90 | 76.70 | 64.90 | 58.10 | 61.90 | 62.40 | 24.80 | 32.50 | 32.90 | 38.70 | 27.20 | 28.70 | |
Of Which: Middle East, Oceania & Africa (Other GEM) Revenue — Share of Consolidated Revenue (%) | 5.70 | 6.30 | 5.90 | 4.90 | 5.60 | 5.60 | 2.30 | 2.80 | 2.80 | 3.20 | 2.60 | 2.60 | |
Of Which: Middle East, Oceania & Africa (Other GEM) Revenue — YoY Change (Actual Exchange Rate / AER %) | 9.60 | 22.90 | 40.50 | -14.00 | 4.10 | -4.60 | -9.10 | 13.20 | 13.90 | 16.80 | 8.70 | 14.60 | |
Of Which: Royalty and Service Income1 | 22.70 | 24.60 | 24.30 | 22.30 | 21.20 | 14.80 | 29.10 | 18.90 | 19.40 | 18.20 | 37.00 | 22.10 | |
Of Which: Royalty and Service Income — YoY Change (Actual Exchange Rate / AER %) | 7.10 | 66.20 | -16.50 | 17.90 | 9.20 | -18.40 | -21.30 | -14.50 | 19.80 | -26.80 | 120.20 | -21.10 | |
Phase 1 Clinical Pipeline — New Molecular Entities (NMEs) | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 2.00 | 2.00 | 5.00 | 5.00 | 5.00 | 6.00 | 7.00 | |
Phase 2 Clinical Pipeline — New Molecular Entities (NMEs) | 5.00 | 6.00 | 7.00 | 9.00 | 8.00 | 9.00 | 8.00 | 10.00 | 11.00 | 12.00 | 12.00 | 15.00 | |
Phase 3 Clinical Pipeline — New Molecular Entities (NMEs) | 8.00 | 8.00 | 8.00 | 8.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 6.00 | |
Phase 3 Clinical Pipeline — Lifecycle Management (LCM) Programs | 4.00 | 4.00 | 5.00 | 11.00 | 11.00 | 12.00 | 11.00 | 11.00 | 13.00 | 15.00 | 17.00 | 19.00 | |
Registration / Filed Stage Pipeline — New Molecular Entities (NMEs) | 4.00 | 2.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | ||||
Registration / Filed Stage Pipeline — Lifecycle Management (LCM) Programs | 8.00 | 7.00 | 9.00 | 14.00 | 14.00 | 10.00 | 16.00 | 11.00 | 10.00 | 7.00 | 23.00 | 22.00 | |
Core Operating Profit (Non-IFRS)17 | 351.70 | 358.90 | 200.90 | 332.40 | 317.40 | 321.80 | 156.40 | 268.40 | 337.70 | 382.30 | 189.30 | 276.80 | |
Core Operating Profit (Non-IFRS) — Margin (% of Revenue) | 29.60 | 29.40 | 18.40 | 27.90 | 28.50 | 29.10 | 14.90 | 25.00 | 28.70 | 31.60 | 18.00 | 24.90 | |
Core Operating Profit (Non-IFRS) — YoY Change (AER %) | 10.80 | 11.50 | 28.50 | 16.10 | -6.00 | -15.80 | -17.40 | 3.50 | 28.70 | 17.10 | -19.00 | -16.00 | |
Core Operating Profit (Non-IFRS) — YoY Change (CER %) | 1.90 | -0.50 | 15.10 | 10.10 | -5.30 | -16.00 | -18.90 | 4.10 | 23.30 | 4.50 | -15.70 | -18.80 | |
Core Revenue (Non-IFRS)2 | 1,187.10 | 1,219.90 | 1,094.50 | 1,191.70 | 1,112.80 | 1,106.70 | 1,051.70 | 1,144.10 | 1,176.00 | 1,208.00 | 1,050.90 | 1,111.20 | |
Core Revenue (Non-IFRS) — YoY Change (AER %) | 6.70 | 10.20 | 4.10 | 4.20 | -5.40 | -8.40 | 0.10 | 3.00 | 12.70 | 14.10 | 9.90 | 1.30 | |
Core Revenue (Non-IFRS) — YoY Change (CER %) | -1.60 | -0.50 | -2.00 | -0.60 | -4.00 | -0.30 | -2.10 | 3.40 | 8.00 | 2.10 | 6.20 | -2.60 | |
Core Cost of Sales (Non-IFRS)2 | -392.40 | -407.00 | -406.20 | -401.20 | -380.20 | -384.90 | -383.50 | -416.90 | -394.40 | -387.10 | -382.00 | -379.40 | |
Core Cost of Sales (Non-IFRS) — YoY Change (AER %) | -3.20 | -5.70 | -5.90 | 3.80 | 3.60 | 0.60 | -0.40 | -9.90 | -14.80 | -20.50 | -24.50 | -14.90 | |
Core Cost of Sales (Non-IFRS) — YoY Change (CER %) | 4.70 | 4.50 | 0.60 | 8.50 | 2.50 | -11.00 | 1.40 | -10.20 | -10.20 | -8.10 | -19.80 | -10.20 | |
Core Gross Profit (Non-IFRS)3 | 794.70 | 812.90 | 688.30 | 790.50 | 732.60 | 721.80 | 668.20 | 727.20 | 781.70 | 820.90 | 668.80 | 731.80 | |
Core Gross Profit (Non-IFRS) — Margin (% of Revenue) | 66.90 | 66.60 | 62.90 | 66.30 | 65.80 | 65.20 | 63.50 | 63.60 | 66.50 | 68.00 | 63.60 | 65.90 | |
Core Gross Profit (Non-IFRS) — YoY Change (AER %) | 8.50 | 12.60 | 3.00 | 8.70 | -6.30 | -12.10 | -0.10 | -0.60 | 11.70 | 11.30 | 3.00 | -4.50 | |
Core Gross Profit (Non-IFRS) — YoY Change (CER %) | -0.00 | 1.70 | -2.80 | 3.90 | -4.80 | -5.20 | -2.60 | -0.20 | 7.00 | -0.50 | -0.20 | -8.10 | |
Core SG&A Expenses (Non-IFRS)2 | -271.80 | -286.60 | -292.10 | -282.80 | -253.70 | -256.00 | -295.80 | -270.70 | -268.40 | -270.20 | -283.90 | -267.60 | |
Core SG&A Expenses (Non-IFRS) — YoY Change (AER %) | -7.10 | -11.90 | 1.20 | -4.50 | 5.50 | 5.20 | -4.20 | -1.10 | -6.00 | -8.80 | -11.60 | -2.00 | |
Core SG&A Expenses (Non-IFRS) — YoY Change (CER %) | 1.10 | -1.60 | 5.90 | -0.10 | 3.90 | 0.80 | -1.90 | -1.50 | -1.50 | 2.50 | -6.80 | 2.10 | |
Core R&D Expenses (Non-IFRS)2 | -171.20 | -167.40 | -195.30 | -175.20 | -161.50 | -143.90 | -216.00 | -170.20 | -175.60 | -168.50 | -195.60 | -187.40 | |
Core R&D Expenses (Non-IFRS) — YoY Change (AER %) | -6.00 | -16.30 | 9.60 | -2.90 | 8.00 | 14.60 | -10.40 | 9.20 | 4.50 | -3.50 | -21.30 | -7.30 | |
Core R&D Expenses (Non-IFRS) — YoY Change (CER %) | 2.10 | -6.80 | 11.50 | 0.20 | 5.30 | -8.30 | -6.80 | 9.00 | 8.80 | 7.70 | -11.20 | -3.30 | |
Core Financial Income (Non-IFRS)2 | 48.30 | 24.50 | 15.80 | 88.70 | 44.70 | 73.00 | 12.90 | 23.80 | 6.10 | 25.00 | 6.50 | 21.60 | |
Core Financial Income (Non-IFRS) — YoY Change (AER %) | 8.30 | -66.40 | 22.90 | 273.00 | 6.30 | 191.70 | 96.90 | 9.90 | -33.20 | -4.80 | -51.00 | -45.30 | |
Core Financial Income (Non-IFRS) — YoY Change (CER %) | 6.90 | -70.20 | 12.30 | 273.00 | 6.30 | 200.00 | 121.10 | 12.30 | -34.30 | -6.20 | -51.90 | -45.40 | |
Core Financial Expenses (Non-IFRS)2 | -90.90 | -61.80 | -50.00 | -120.50 | -80.50 | -104.30 | -47.40 | -56.60 | -49.40 | -55.10 | -41.20 | -65.10 | |
Core Financial Expenses (Non-IFRS) — YoY Change (AER %) | -12.90 | 40.80 | -5.60 | -112.90 | -63.00 | -89.40 | -15.00 | 13.00 | -11.00 | -0.50 | -18.10 | 14.60 | |
Core Financial Expenses (Non-IFRS) — YoY Change (CER %) | -6.60 | 43.50 | -3.20 | -119.10 | -64.70 | -27.60 | -14.90 | 13.00 | -6.90 | 2.50 | -41.60 | 15.10 | |
Core Share of Profit/Loss of Investments Accounted for Using the Equity Method | -0.50 | 0.50 | -0.40 | 0.80 | -0.50 | -0.10 | -0.40 | -0.10 | 1.30 | 0.40 | 1.60 | 2.10 | |
Core Profit Before Tax (Non-IFRS)2 | 308.60 | 322.20 | 166.30 | 301.40 | 281.10 | 290.40 | 121.40 | 253.40 | 295.70 | 352.60 | 156.20 | 235.40 | |
Core Profit Before Tax (Non-IFRS) — YoY Change (AER %) | 9.80 | 10.90 | 36.90 | 19.00 | -4.90 | -17.60 | -22.30 | 7.60 | 29.30 | 18.10 | -25.60 | -19.50 | |
Core Profit Before Tax (Non-IFRS) — YoY Change (CER %) | 1.40 | -2.40 | 19.50 | 10.70 | -4.40 | -17.90 | -23.00 | 8.60 | 23.90 | 4.70 | -25.90 | -22.60 | |
Core Income Tax Expense (Non-IFRS)2 | -61.80 | -79.30 | -25.70 | -66.30 | -79.50 | -53.30 | -44.70 | -43.50 | -83.30 | -75.70 | -43.00 | 0.50 | |
Core Income Tax Expense (Non-IFRS) — YoY Change (AER %) | 22.20 | -48.60 | 42.60 | -52.50 | 4.70 | 29.60 | -4.00 | -70.30 | -53.60 | -16.20 | 15.20 | 17.90 | |
Core Income Tax Expense (Non-IFRS) — YoY Change (CER %) | 26.40 | -35.50 | 50.40 | -38.10 | -15.60 | 16.40 | -5.10 | -64.50 | -50.60 | -7.50 | 20.70 | 20.00 | |
Core Net Profit for the Period (Non-IFRS)2 | 246.80 | 242.90 | 140.60 | 235.10 | 201.60 | 237.10 | 76.80 | 209.90 | 212.30 | 276.90 | 113.20 | 235.90 | |
Core Net Profit for the Period (Non-IFRS) — YoY Change (AER %) | 22.40 | 2.50 | 83.20 | 12.00 | -5.00 | -14.40 | -32.20 | -11.00 | 21.80 | 18.60 | -28.90 | -9.40 | |
Core Net Profit for the Period (Non-IFRS) — YoY Change (CER %) | 12.40 | -10.90 | 60.10 | 5.10 | -12.20 | -15.90 | -33.60 | -10.20 | 15.60 | 3.90 | -27.50 | -9.50 | |
Core Non-Controlling Interests (Non-IFRS)2 | -3.00 | -0.10 | -0.10 | -0.10 | -0.10 | 0.00 | -0.10 | 0.00 | -0.10 | -0.10 | -0.10 | ||
Core Non-Controlling Interests (Non-IFRS) — YoY Change (AER %) | 58.80 | -65.10 | -10.70 | -103.10 | -18.70 | 29.90 | -142.80 | -28.60 | -2.70 | -351.00 | -11.10 | -61.10 | |
Core Non-Controlling Interests (Non-IFRS) — YoY Change (CER %) | 58.00 | -55.80 | -16.40 | -114.50 | -27.10 | -492.00 | -147.30 | -28.50 | -6.20 | -332.00 | -10.20 | -59.80 | |
Core Net Profit Attributable to Owners of the Company (Non-IFRS)2 | 246.80 | 242.90 | 140.60 | 235.00 | 201.60 | 237.00 | 76.70 | 209.80 | 212.30 | 276.80 | 113.20 | 235.90 | |
Core Net Profit Attributable to Owners of the Company (Non-IFRS) — YoY Change (AER %) | 22.40 | 2.50 | 83.20 | 12.00 | -5.00 | -14.40 | -32.30 | -11.00 | 21.80 | 18.60 | -28.90 | -9.40 | |
Core Net Profit Attributable to Owners of the Company (Non-IFRS) — YoY Change (CER %) | 12.40 | -10.90 | 60.20 | 5.10 | -12.20 | -15.90 | -33.70 | -10.20 | 15.60 | 3.90 | -27.50 | -9.50 | |
Core Basic EPS (Non-IFRS)2 | 155.00 | 154.00 | 89.00 | 149.00 | 128.00 | 151.00 | 49.00 | 132.00 | 134.00 | 176.00 | 72.00 | 150.00 | |
Core Basic EPS (Non-IFRS) — YoY Change (AER %) | 21.00 | 1.50 | 83.40 | 12.40 | -4.70 | -14.10 | -32.80 | -12.00 | 20.50 | 17.50 | -29.50 | -10.30 | |
Core Basic EPS (Non-IFRS) — YoY Change (CER %) | 11.10 | -11.80 | 60.30 | 5.40 | -11.90 | -16.60 | -34.20 | -11.10 | 14.50 | 2.90 | -28.20 | -10.30 | |
Reported Operating Profit (IFRS Quarterly & Annual)17 | |||||||||||||
Reported Consolidated Revenue (IFRS)2 | 1,187.10 | 1,219.90 | 1,094.50 | 1,191.70 | 1,112.80 | 1,106.70 | 1,053.40 | 1,144.10 | 1,176.00 | 1,208.00 | 1,050.90 | 1,111.20 | |
Reported Consolidated Revenue (IFRS) — YoY Change (AER %) | 6.70 | 10.20 | 3.90 | 4.20 | -5.40 | -8.40 | 0.20 | 3.00 | 12.70 | 14.10 | 9.90 | 1.30 | |
Reported Consolidated Revenue (IFRS) — YoY Change (CER %) | -1.60 | -0.50 | -2.20 | -0.60 | -4.00 | -0.30 | -2.00 | 3.40 | 8.00 | 2.10 | 6.20 | -2.60 | |
Reported Cost of Sales (IFRS)2 | -392.10 | -406.70 | -405.70 | -401.10 | -380.10 | -384.70 | -382.10 | -416.90 | -394.30 | -387.00 | -382.50 | -379.50 | |
Reported Cost of Sales (IFRS) — YoY Change (AER %) | -3.20 | -5.70 | -6.20 | 3.80 | 3.60 | 0.60 | 0.10 | -9.90 | -14.80 | -20.50 | -23.50 | -13.00 | |
Reported Cost of Sales (IFRS) — YoY Change (CER %) | 4.70 | 4.50 | 0.40 | 8.50 | 2.50 | -7.90 | 1.80 | -10.20 | -10.10 | -8.10 | -18.80 | -8.30 | |
Reported Gross Profit (IFRS)3 | 795.00 | 813.20 | 688.80 | 790.60 | 732.70 | 722.00 | 671.30 | 727.30 | 781.70 | 821.00 | 668.40 | 731.70 | |
Reported Gross Profit (IFRS) — Margin (% of Revenue) | 67.00 | 66.70 | 62.90 | 66.30 | 65.80 | 65.20 | 63.70 | 63.60 | 66.50 | 68.00 | 63.60 | 65.80 | |
Reported Gross Profit (IFRS) — YoY Change (AER %) | 8.50 | 12.60 | 2.60 | 8.70 | -6.30 | -12.10 | 0.40 | -0.60 | 11.80 | 11.30 | 3.40 | -3.80 | |
Reported Gross Profit (IFRS) — YoY Change (CER %) | 0.00 | 1.70 | -3.20 | 3.90 | -4.80 | -4.00 | -2.00 | -0.20 | 7.00 | -0.50 | 0.20 | -7.40 | |
Reported SG&A Expenses (IFRS)2 | -271.70 | -286.50 | -292.00 | -282.80 | -253.60 | -255.90 | -295.90 | -270.60 | -268.30 | -270.00 | -285.20 | -267.50 | |
Reported SG&A Expenses (IFRS) — YoY Change (AER %) | -7.20 | -12.00 | 1.30 | -4.50 | 5.50 | 5.20 | -3.70 | -1.10 | -6.10 | -8.80 | -11.90 | -2.00 | |
Reported SG&A Expenses (IFRS) — YoY Change (CER %) | 1.10 | -1.60 | 6.00 | -0.10 | 3.90 | 0.70 | -1.40 | -1.60 | -1.50 | 2.40 | -7.10 | 2.10 | |
Reported R&D Expenses (IFRS)2 | -171.20 | -167.40 | -195.30 | -175.20 | -161.50 | -143.90 | -216.00 | -170.20 | -175.60 | -168.50 | -195.90 | -187.40 | |
Reported R&D Expenses (IFRS) — YoY Change (AER %) | -6.00 | -16.30 | 9.60 | -3.00 | 8.00 | 14.60 | -10.30 | 9.20 | 4.60 | -3.50 | -21.70 | -7.30 | |
Reported R&D Expenses (IFRS) — YoY Change (CER %) | 2.00 | -6.80 | 11.50 | 0.20 | 5.30 | -8.30 | -6.60 | 9.00 | 8.80 | 7.70 | -11.60 | -3.20 | |
Reported Amortization of Intangible Assets Associated with Products (IFRS)2 | -106.80 | -105.50 | -107.40 | -136.20 | -131.40 | -129.30 | -136.50 | -134.20 | -138.90 | -138.60 | -133.80 | -133.80 | |
Reported Amortization of Intangible Assets Associated with Products (IFRS) — YoY Change (AER %) | 18.70 | 18.40 | 21.40 | -1.50 | 5.40 | 6.70 | -2.00 | -0.30 | -6.20 | -12.50 | -16.90 | -3.10 | |
Reported Amortization of Intangible Assets Associated with Products (IFRS) — YoY Change (CER %) | 25.30 | 26.20 | 24.10 | 2.70 | 3.10 | -0.40 | 1.90 | -0.60 | -0.80 | 0.80 | -6.10 | 1.10 | |
Reported Other Operating Income (IFRS)2 | 7.20 | 8.30 | 2.30 | -0.90 | 1.50 | 22.00 | 10.40 | 2.40 | 3.10 | 10.90 | 9.30 | 0.90 | |
Reported Other Operating Income (IFRS) — YoY Change (AER %) | 384.00 | -62.50 | -78.30 | 39.70 | -51.40 | 102.70 | 11.90 | 163.30 | -45.90 | 155.70 | 6.70 | -72.10 | |
Reported Other Operating Income (IFRS) — YoY Change (CER %) | 356.00 | -64.30 | -76.60 | 40.30 | -50.50 | -26.70 | 11.00 | 167.60 | -45.10 | 135.40 | -8.40 | -70.00 | |
Reported Other Operating Expenses (IFRS)2 | -46.40 | -55.20 | -465.10 | -20.90 | -45.00 | -28.10 | -41.80 | -87.00 | -14.30 | -64.30 | -61.60 | -35.40 | |
Reported Other Operating Expenses (IFRS) — YoY Change (AER %) | -2.90 | -96.80 | -10.10 | 75.90 | -215.00 | 56.30 | 32.20 | -145.40 | 81.50 | -95.30 | -250.00 | 20.00 | |
Reported Other Operating Expenses (IFRS) — YoY Change (CER %) | 4.60 | -73.40 | -10.10 | 77.00 | -214.00 | -34.20 | 32.50 | -144.30 | 81.20 | -72.80 | -219.00 | 25.00 | |
Reported Financial Income (IFRS)2 | 47.70 | 24.60 | 15.80 | 88.30 | 44.40 | 73.80 | 18.70 | 25.20 | 6.50 | 30.70 | 6.60 | 22.50 | |
Reported Financial Income (IFRS) — YoY Change (AER %) | 7.40 | -66.60 | -15.60 | 250.00 | 5.80 | 140.40 | 183.00 | 11.80 | -30.20 | 16.00 | -52.60 | -45.90 | |
Reported Financial Income (IFRS) — YoY Change (CER %) | 6.10 | -70.40 | -22.90 | 250.00 | 5.80 | -18.50 | 207.00 | 10.80 | -32.10 | 14.50 | -53.50 | -46.20 | |
Reported Financial Expenses (IFRS)2 | -96.50 | -63.80 | -54.30 | -124.10 | -83.10 | -107.20 | -50.30 | -63.80 | -70.90 | -59.70 | -47.80 | -67.30 | |
Reported Financial Expenses (IFRS) — YoY Change (AER %) | -16.10 | 40.40 | -7.90 | -94.60 | -17.30 | -79.50 | -5.20 | 5.30 | -22.10 | -0.20 | 2.60 | 15.60 | |
Reported Financial Expenses (IFRS) — YoY Change (CER %) | -9.40 | 43.10 | -5.70 | -100.00 | -18.60 | -23.10 | -5.10 | 6.40 | -18.80 | 2.80 | -41.50 | 16.50 | |
Reported Share of Profit/Loss of Equity Method Investments (IFRS) | -0.50 | 0.50 | -0.40 | 0.80 | -2.10 | -0.50 | -0.80 | -2.00 | -0.50 | -0.70 | 3.70 | 1.10 | |
Reported Income Tax Expense (IFRS) | 36.50 | -49.50 | 86.60 | -30.10 | -39.90 | -26.40 | 4.20 | -2.60 | -27.30 | -41.30 | 44.50 | 44.50 | |
Reported Net Profit for the Period (IFRS) | 192.50 | 113.30 | -368.40 | 103.70 | -11.70 | 124.30 | -103.10 | 23.80 | 92.10 | 95.30 | -3.00 | 105.80 | |
Reported Non-Controlling Interests (IFRS)2 | -2.00 | -0.10 | -0.10 | -0.10 | -0.10 | 0.00 | -0.10 | 0.00 | -0.10 | -0.10 | -0.10 | ||
Reported Non-Controlling Interests (IFRS) — YoY Change (AER %) | 58.80 | -65.10 | -10.70 | -103.10 | -18.70 | 29.90 | -142.80 | -28.60 | -2.70 | -351.00 | -11.10 | -61.10 | |
Reported Non-Controlling Interests (IFRS) — YoY Change (CER %) | 58.00 | -55.80 | -16.40 | -114.50 | -27.10 | -492.00 | -147.30 | -28.50 | -6.20 | -332.00 | -10.20 | -59.80 | |
Reported Net Profit Attributable to Owners of the Company (IFRS) | 192.40 | 113.20 | -368.50 | 103.60 | -11.80 | 124.20 | -103.20 | 23.80 | 92.00 | 95.20 | -3.00 | 105.70 | |
Reported Basic EPS (IFRS) | 120.80 | 71.70 | -233.20 | 65.60 | -7.50 | 79.40 | -65.20 | 15.00 | 58.20 | 60.70 | -192.00 | 67.40 | |
Weighted Average Number of Basic Shares Outstanding | 1,593.00 | 1,580.00 | 1,580.00 | 1,580.00 | 1,575.00 | 1,565.00 | 1,581.00 | 1,585.00 | 1,581.00 | 1,569.00 | 1,569.00 | 1,569.00 | |
Reported-to-Core Net Profit Adjustment — Amortization of Product Intangible Assets (Pre-Tax) | 85.90 | 83.10 | 80.10 | 108.70 | 106.50 | 101.80 | 107.80 | 106.10 | 109.80 | 109.60 | 107.70 | 105.30 | |
Reported-to-Core Net Profit Adjustment — Impairment of Product Intangible Assets (Pre-Tax) | 0.60 | 3.70 | 36.10 | 4.50 | 69.30 | 1.80 | 51.30 | 0.50 | 2.80 | 17.00 | 9.10 | 2.80 | |
Reported-to-Core Net Profit Adjustment — Other Operating & Non-Operating Non-Core Items | 30.10 | 37.20 | 390.30 | 16.70 | 33.90 | 7.90 | -4.20 | 0.70 | 12.70 | 42.00 | 40.90 | 19.30 | |
Net Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1) | 304.30 | 127.60 | 74.50 | 373.20 | 378.30 | 215.40 | 222.20 | 383.70 | 281.00 | 170.30 | 278.50 | 146.50 | |
Free Cash Flow (IFRS Operating Cash Flow Less PP&E Acquisition) | 259.60 | 73.80 | 28.10 | 331.70 | 338.10 | 167.50 | 173.40 | 338.60 | 231.50 | 112.90 | 234.00 | 99.40 | |
Adjusted Free Cash Flow (Non-IFRS)2 | 257.10 | 68.60 | 58.60 | 100.50 | 335.30 | 190.10 | 200.70 | 320.80 | 223.80 | 23.70 | 247.10 | 107.40 | |
Adjustment for Change in Cash Temporarily Held on Behalf of Third Parties | -5.00 | 33.40 | 47.20 | -40.40 | 6.60 | 13.20 | 3.00 | -9.40 | -3.10 | 11.60 | 8.40 | 39.80 | |
Proceeds from Sales of Business, Net of Cash and Cash Equivalents Divested | 12.20 | 10.50 | 0.50 | 3.20 | 0.30 | 29.30 | 11.00 | 1.30 | 5.40 | 2.90 | 19.60 | 0.00 | |
Adjusted Net Debt to Adjusted EBITDA Leverage Ratio(×)8 | 2.50 | 2.70 | 2.60 | 2.70 | 2.70 | 2.90 | 2.80 | 2.70 | 2.90 | 3.10 | 3.10 | ||
Book Value of Bonds and Loans (Gross Debt, IFRS) | -4,575.60 | -4,940.00 | -4,881.80 | -4,853.30 | -4,645.30 | -4,505.90 | -4,505.90 | ||||||
Net Debt (IFRS Book Value Basis) | -4,157.10 | -4,479.00 | -4,286.80 | -4,198.40 | -3,963.80 | -4,155.90 | -4,130.20 | -4,346.00 | -4,192.20 | -4,676.70 | -4,386.00 | ||
Hybrid Subordinated Debt 50% Equity Credit Adjustment | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | ||
Adjusted Gross Debt (After Hybrid Equity Credit & FX Adjustment) | -4,352.60 | -4,418.70 | -4,418.70 | -4,299.10 | -4,334.20 | -4,495.30 | -4,969.10 | -4,983.70 | |||||
Adjusted Net Debt | -3,917.90 | -4,012.60 | -3,817.60 | -3,773.60 | -3,657.30 | -3,965.00 | -3,975.50 | -4,026.40 | -4,195.10 | -4,275.70 | -4,091.30 | ||
Adjusted EBITDA (Last Twelve Months / LTM) | 1,540.30 | 1,503.80 | 1,457.20 | 1,404.50 | 1,353.90 | 1,372.40 | 1,441.00 | 1,471.00 | 1,459.20 | 1,382.40 | 1,319.90 | 1,358.90 | |
Consolidated EBITDA (Quarterly & Annual) | 247.20 | 361.40 | -231.80 | 231.80 | 0.00 | 361.50 | 0.00 | 0.00 | 0.00 | 355.40 | 0.00 | 0.00 | |
Consolidated Adjusted EBITDA (Quarterly & Annual) | 426.60 | 433.40 | 274.50 | 404.50 | 389.60 | 388.60 | 226.60 | 354.60 | 409.70 | 450.10 | 253.30 | 344.40 | |
Dividends Paid (Cash Outflow — Exhibit 99.1) | 0.00 | -150.10 | 0.00 | 0.00 | 0.00 | -145.30 | 0.00 | 0.00 | 0.00 | -138.10 | 0.00 | 0.00 | |
Interest Paid (Cash Outflow — Exhibit 99.1) | 0.00 | -15.60 | 0.00 | 0.00 | 0.00 | -16.70 | 0.00 | 0.00 | 0.00 | -15.50 | 0.00 | 0.00 | |
Period-End Total Consolidated Assets (Kessan Tanshin) | 15,271,498.00 | 15,663,271.00 | 15,453,113.00 | 15,408,774.00 | 14,470,300.00 | 14,004,537.00 | 14,248,344.00 | 15,106,844.00 | 14,573,000.00 | 16,227,683.00 | 15,108,792.00 | 14,222,947.00 | |
Period-End Total Consolidated Equity (Kessan Tanshin) | 7,417,176.00 | 7,558,876.00 | 7,774,800.00 | 7,644,091.00 | 7,131,690.00 | 6,866,179.00 | 6,935,979.00 | 7,419,191.00 | 6,921,597.00 | 7,799,232.00 | 7,274,005.00 | 6,742,607.00 | |
Period-End Equity Attributable to Owners of the Parent (Kessan Tanshin) | 7,416,185.00 | 7,557,887.00 | 7,773,592.00 | 7,642,943.00 | 7,130,697.00 | 6,865,259.00 | 6,935,084.00 | 7,418,274.00 | 6,920,754.00 | 7,798,417.00 | 7,273,264.00 | 6,741,934.00 | |
Period-End Equity Attributable to Owners to Total Assets Ratio (%) | 48.60 | 48.30 | 50.30 | 49.60 | 49.30 | 49.00 | 48.70 | 49.10 | 47.50 | 48.10 | 48.10 | 47.40 | |
Period-End Book Value per Share (Equity Attributable to Owners per Share) | 4,642.52 | 4,782.57 | 4,920.50 | 4,838.54 | 4,514.26 | 4,395.19 | 4,407.01 | 4,679.77 | 4,365.91 | 4,970.05 | 4,635.56 | 4,297.22 | |
Period-End Total Shares Issued (Including Treasury Shares) | 1,602,218,559.00 | 1,591,273,909.00 | 1,591,229,109.00 | 1,590,987,809.00 | 1,590,985,809.00 | 1,590,962,609.00 | 1,590,949,609.00 | 1,590,937,609.00 | 1,590,937,609.00 | 1,582,418,725.00 | 1,582,418,725.00 | 1,582,392,825.00 | |
Period-End Treasury Shares Held | 4,769,662.00 | 10,976,853.00 | 11,392,279.00 | 11,391,398.00 | 11,391,535.00 | 28,968,756.00 | 17,299,963.00 | 5,758,360.00 | 5,757,015.00 | 13,336,181.00 | 13,405,261.00 | 13,486,498.00 | |
Annual Dividend per Share | 204.00 | 204.00 | 204.00 | 200.00 | 200.00 | 200.00 | 200.00 | 196.00 | 196.00 | 196.00 | 196.00 | 188.00 | |
Full-Year Guidance — Consolidated Revenue (IFRS) | 4,700,000.00 | 4,640,000.00 | 4,640,000.00 | 4,530,000.00 | 4,500,000.00 | 4,530,000.00 | 4,530,000.00 | 4,590,000.00 | 4,480,000.00 | 4,350,000.00 | 4,350,000.00 | 3,980,000.00 | |
Full-Year Guidance — Consolidated Operating Profit (IFRS) | 453,000.00 | 420,000.00 | 420,000.00 | 410,000.00 | 400,000.00 | 475,000.00 | 475,000.00 | 344,000.00 | 265,000.00 | 225,000.00 | 225,000.00 | 225,000.00 | |
Full-Year Guidance — Consolidated Profit Before Tax (IFRS) | 270,000.00 | 252,000.00 | 252,000.00 | 245,000.00 | 243,000.00 | 307,000.00 | 307,000.00 | 162,000.00 | 93,000.00 | 55,000.00 | 55,000.00 | 70,000.00 | |
Full-Year Guidance — Net Profit Attributable to Owners (IFRS) | 209,000.00 | 166,000.00 | 166,000.00 | 154,000.00 | 153,000.00 | 228,000.00 | 228,000.00 | 118,000.00 | 68,000.00 | 58,000.00 | 58,000.00 | 93,000.00 | |
Full-Year Guidance — Reported Basic EPS (IFRS) | 131.28 | 104.26 | 104.26 | 97.78 | 97.14 | 144.81 | 144.81 | 74.68 | 43.03 | 36.70 | 36.70 | 59.45 | |
U.S. Dollar (USD/JPY) — Actual Period-to-Date Average Exchange Rate9 | 160.00 | 159.00 | 150.00 | 148.00 | 146.00 | 145.00 | 152.00 | 152.00 | 154.00 | 155.00 | 144.00 | 143.00 | |
U.S. Dollar (USD/JPY) — Full-Year Exchange Rate Assumption | 158.00 | 156.00 | 156.00 | 150.00 | 147.00 | 150.00 | 150.00 | 153.00 | 150.00 | 150.00 | 150.00 | 137.00 | |
U.S. Dollar Sensitivity (1% JPY Depreciation vs. USD) — Impact on Revenue (IFRS) | 92.40 | 206.10 | 206.10 | 40.10 | 92.20 | 234.30 | 234.30 | 34.30 | 86.40 | 225.60 | 225.60 | 207.00 | |
U.S. Dollar Sensitivity (1% JPY Depreciation vs. USD) — Impact on Operating Profit (IFRS) | -5.70 | 4.20 | 4.20 | -0.20 | -1.70 | 8.30 | 8.30 | -6.20 | -6.70 | 15.00 | 15.00 | 15.40 | |
U.S. Dollar Sensitivity (1% JPY Depreciation vs. USD) — Impact on Net Profit (IFRS) | -8.10 | -3.40 | -3.40 | -1.30 | -3.70 | -1.10 | -1.10 | -6.30 | -8.50 | 5.00 | 5.00 | 5.80 | |
U.S. Dollar Sensitivity (1% JPY Depreciation vs. USD) — Impact on Core Operating Profit (Non-IFRS) | 10.70 | 37.30 | 37.30 | 5.80 | 14.70 | 52.50 | 52.50 | 3.80 | 16.40 | 67.20 | 67.20 | 65.10 | |
U.S. Dollar Sensitivity (1 JPY Depreciation vs. USD) — Impact on Revenue (IFRS) | 58.90 | 132.10 | 132.10 | 25.60 | 62.30 | 156.20 | 156.20 | 22.10 | 57.60 | 150.40 | 150.40 | 151.10 | |
U.S. Dollar Sensitivity (1 JPY Depreciation vs. USD) — Impact on Operating Profit (IFRS) | -3.60 | 2.70 | 2.70 | -0.10 | -1.20 | 5.50 | 5.50 | -4.00 | -4.50 | 10.00 | 10.00 | 11.20 | |
U.S. Dollar Sensitivity (1 JPY Depreciation vs. USD) — Impact on Net Profit (IFRS) | -5.20 | -2.20 | -2.20 | -0.80 | -2.50 | -0.70 | -0.70 | -4.00 | -5.70 | 3.30 | 3.30 | 4.20 | |
U.S. Dollar Sensitivity (1 JPY Depreciation vs. USD) — Impact on Core Operating Profit (Non-IFRS) | 6.80 | 23.90 | 23.90 | 3.70 | 10.00 | 35.00 | 35.00 | 2.50 | 10.90 | 44.80 | 44.80 | 47.50 | |
Euro (EUR/JPY) — Actual Period-to-Date Average Exchange Rate9 | 185.00 | 185.00 | 174.00 | 170.00 | 166.00 | 162.00 | 163.00 | 165.00 | 166.00 | 167.00 | 156.00 | 155.00 | |
Euro (EUR/JPY) — Full-Year Exchange Rate Assumption | 182.00 | 182.00 | 182.00 | 174.00 | 170.00 | 160.00 | 160.00 | 165.00 | 165.00 | 160.00 | 160.00 | 145.00 | |
Euro Sensitivity (1% JPY Depreciation vs. EUR) — Impact on Revenue (IFRS) | 30.70 | 69.20 | 69.20 | 12.60 | 29.80 | 65.60 | 65.60 | 11.30 | 27.90 | 63.80 | 63.80 | 57.20 | |
Euro Sensitivity (1% JPY Depreciation vs. EUR) — Impact on Operating Profit (IFRS) | -15.40 | -28.40 | -28.40 | -5.40 | -13.60 | -28.20 | -28.20 | -9.40 | -22.80 | -49.40 | -49.40 | -37.40 | |
Euro Sensitivity (1% JPY Depreciation vs. EUR) — Impact on Net Profit (IFRS) | -12.70 | -20.60 | -20.60 | -3.70 | -9.30 | -25.00 | -25.00 | -7.80 | -19.00 | -41.40 | -41.40 | -32.50 | |
Euro Sensitivity (1% JPY Depreciation vs. EUR) — Impact on Core Operating Profit (Non-IFRS) | -9.30 | -17.70 | -17.70 | -3.50 | -8.80 | -17.10 | -17.10 | -7.20 | -17.30 | -37.50 | -37.50 | -30.30 | |
Euro Sensitivity (1 JPY Depreciation vs. EUR) — Impact on Revenue (IFRS) | 17.10 | 38.00 | 38.00 | 6.90 | 17.20 | 41.00 | 41.00 | 6.80 | 16.90 | 39.90 | 39.90 | 39.50 | |
Euro Sensitivity (1 JPY Depreciation vs. EUR) — Impact on Operating Profit (IFRS) | -8.50 | -15.60 | -15.60 | -2.90 | -7.80 | -17.60 | -17.60 | -5.70 | -13.80 | -30.90 | -30.90 | -25.80 | |
Euro Sensitivity (1 JPY Depreciation vs. EUR) — Impact on Net Profit (IFRS) | -7.10 | -11.30 | -11.30 | -2.00 | -5.30 | -15.70 | -15.70 | -4.70 | -11.50 | -25.90 | -25.90 | -22.40 | |
Euro Sensitivity (1 JPY Depreciation vs. EUR) — Impact on Core Operating Profit (Non-IFRS) | -5.20 | -9.70 | -9.70 | -1.90 | -5.10 | -10.70 | -10.70 | -4.30 | -10.50 | -23.50 | -23.50 | -20.90 | |
Russian Ruble (RUB/JPY) — Actual Period-to-Date Average Exchange Rate5 | 2.00 | 2.10 | 1.90 | 1.80 | 1.80 | 1.80 | 1.60 | 1.60 | 1.70 | 1.70 | 1.60 | 1.60 | |
Russian Ruble (RUB/JPY) — Full-Year Exchange Rate Assumption | 2.00 | 2.00 | 2.00 | 1.90 | 1.80 | 1.70 | 1.70 | 1.60 | 1.70 | 1.60 | 1.60 | 1.60 | |
Russian Ruble Sensitivity (1% JPY Depreciation vs. RUB) — Impact on Revenue (IFRS) | 1.80 | 4.50 | 4.50 | 0.60 | 1.60 | 5.60 | 5.60 | 0.40 | 1.70 | 4.50 | 4.50 | 4.40 | |
Russian Ruble Sensitivity (1% JPY Depreciation vs. RUB) — Impact on Operating Profit (IFRS) | 1.00 | 2.70 | 2.70 | 0.20 | 0.70 | 3.30 | 3.30 | 0.10 | 0.90 | 2.60 | 2.60 | 2.60 | |
Russian Ruble Sensitivity (1% JPY Depreciation vs. RUB) — Impact on Net Profit (IFRS) | 0.80 | 1.80 | 1.80 | 0.10 | 0.40 | 2.50 | 2.50 | 0.10 | 0.70 | 2.10 | 2.10 | 2.00 | |
Russian Ruble Sensitivity (1% JPY Depreciation vs. RUB) — Impact on Core Operating Profit (Non-IFRS) | 1.10 | 2.90 | 2.90 | 0.30 | 0.90 | 3.80 | 3.80 | 0.20 | 1.10 | 3.10 | 3.10 | 3.00 | |
Chinese Yuan (CNY/JPY) — Actual Period-to-Date Average Exchange Rate5 | 23.50 | 23.30 | 21.10 | 20.70 | 20.30 | 20.10 | 21.10 | 21.10 | 21.30 | 21.40 | 20.10 | 20.00 | |
Chinese Yuan (CNY/JPY) — Full-Year Exchange Rate Assumption | 23.50 | 22.40 | 22.40 | 21.10 | 20.50 | 20.50 | 20.50 | 21.20 | 21.20 | 20.90 | 20.90 | 19.80 | |
Chinese Yuan Sensitivity (1% JPY Depreciation vs. CNY) — Impact on Revenue (IFRS) | 9.50 | 19.90 | 19.90 | 3.70 | 9.50 | 19.50 | 19.50 | 4.50 | 10.00 | 19.90 | 19.90 | 17.30 | |
Chinese Yuan Sensitivity (1% JPY Depreciation vs. CNY) — Impact on Operating Profit (IFRS) | 5.90 | 12.20 | 12.20 | 2.20 | 5.90 | 11.80 | 11.80 | 3.00 | 6.50 | 12.20 | 12.20 | 10.10 | |
Chinese Yuan Sensitivity (1% JPY Depreciation vs. CNY) — Impact on Net Profit (IFRS) | 4.60 | 8.20 | 8.20 | 1.40 | 3.70 | 8.90 | 8.90 | 2.40 | 5.20 | 9.80 | 9.80 | 7.80 | |
Chinese Yuan Sensitivity (1% JPY Depreciation vs. CNY) — Impact on Core Operating Profit (Non-IFRS) | 5.90 | 12.20 | 12.20 | 2.20 | 5.90 | 11.90 | 11.90 | 3.00 | 6.50 | 12.20 | 12.20 | 10.10 | |
Brazilian Real (BRL/JPY) — Actual Period-to-Date Average Exchange Rate5 | 31.20 | 31.30 | 27.60 | 27.00 | 26.20 | 25.60 | 27.40 | 27.90 | 28.90 | 30.40 | 29.10 | 28.90 | |
Brazilian Real (BRL/JPY) — Full-Year Exchange Rate Assumption | 30.70 | 29.50 | 29.50 | 27.40 | 27.00 | 25.90 | 25.90 | 27.20 | 28.60 | 30.40 | 30.40 | 28.50 | |
Brazilian Real Sensitivity (1% JPY Depreciation vs. BRL) — Impact on Revenue (IFRS) | 6.50 | 14.20 | 14.20 | 2.00 | 5.50 | 12.90 | 12.90 | 1.40 | 4.10 | 12.60 | 12.60 | 10.90 | |
Brazilian Real Sensitivity (1% JPY Depreciation vs. BRL) — Impact on Operating Profit (IFRS) | 5.30 | 11.50 | 11.50 | 1.30 | 4.00 | 9.70 | 9.70 | 0.90 | 2.60 | 8.70 | 8.70 | 7.00 | |
Brazilian Real Sensitivity (1% JPY Depreciation vs. BRL) — Impact on Net Profit (IFRS) | 4.20 | 7.70 | 7.70 | 0.80 | 2.50 | 6.40 | 6.40 | 0.70 | 2.00 | 6.90 | 6.90 | 5.40 | |
Brazilian Real Sensitivity (1% JPY Depreciation vs. BRL) — Impact on Core Operating Profit (Non-IFRS) | 5.40 | 11.60 | 11.60 | 1.40 | 4.00 | 9.80 | 9.80 | 0.90 | 2.60 | 8.80 | 8.80 | 7.10 | |
Spot Exchange Rate — Japanese Yen per U.S. Dollar (FRED DEXJPUS) | 157.25 | 162.61 | 159.08 | 156.80 | 147.97 | 144.17 | 149.90 | 157.37 | 143.25 | 160.88 | 151.22 | 140.92 | |
Spot Exchange Rate — U.S. Dollars per Euro (FRED DEXUSEU) | 1.13 | 1.14 | 1.15 | 1.17 | 1.17 | 1.18 | 1.08 | 1.04 | 1.11 | 1.07 | 1.08 | 1.11 | |
U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (FRED PCU325412325412) | 929.25 | 926.18 | 926.04 | 919.30 | 918.73 | 914.85 | 916.46 | 918.46 | 918.07 | 913.98 | 908.96 | 896.41 | |
U.S. Consumer Price Index — Medical Care Commodities (FRED CUSR0000SAM1) | 402.83 | 408.97 | 414.03 | 416.47 | 417.57 | 413.00 | 412.38 | 413.71 | 416.81 | 408.92 | 410.37 | ||
U.S. Personal Consumption Expenditures — Health Care Services, SAAR (FRED DHLCRC1M027SBEA) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal Year Convention: Takeda's fiscal year ends on March 31. Following the PostgreSQL database convention (fiscal_periods), fiscal years are labeled by the calendar year in which the period ends (e.g., FY2026 ended March 31, 2026; FY2027 Q1 ended June 30, 2026; FY2027 Q2 ended September 30, 2026). Note that Takeda's investor relations documents refer to the year ended March 31, 2026 as 'FY2025' and the year ending March 31, 2027 as 'FY2026'.
- Period Splitting (Step 4): Cumulative year-to-date cash flow, capital expenditure, and depreciation/amortization figures in quarterly Form 6-K filings and Quarterly Data Books are converted to standalone quarters using Q2 = H1 − Q1, Q3 = 9M − H1, and Q4 = FY − 9M.
- Consolidated vs. Unconsolidated Parent Accounting (Step 4): Takeda's Consolidated Financial Statements are prepared under IFRS, whereas the Unconsolidated Parent Financial Statements (Takeda Pharmaceutical Company Limited) in the AGM Convocation Notice are prepared under Japanese GAAP (J-GAAP) and include intercompany sales, purchases, royalties, and dividends with subsidiaries. Consequently, Consolidated minus Unconsolidated subtraction is not performed, and Unconsolidated Parent metrics are presented in their own dedicated group.
Không hiện vì thiếu các kỳ gần đây (202)
- Divested / Discontinued Products (PENTASA, ALOFISEL, RECOMBINATE, VELCADE, EXKIVITY, ROZEREM, LOTRIGA, ACTOVEGIN, Historical Rare Hematology / Rare Genetics Sub-Totals) — Discontinued or ceased separate quarterly reporting prior to the 3 most recent quarters (FY2026 Q4–FY2027 Q2)
- DB Legacy Segment Members (Cardiovascular & Metabolic, General Medicine, Consumer Healthcare, Nesina, Amitiza, Colcrys, Uloric, Natpara, Shire Legacy Segments) — Superseded therapeutic area classifications discontinued prior to FY2025
- DB Derived Metrics (gross-profit, ebitda, free-cash-flow, net-debt, cash-and-short-term-investments) — Excluded per Step 4 rule prohibiting multi-line arithmetic formulas; disclosed IFRS & Core figures from Form 6-K Data Books are shown instead
- Forward-Looking Revenue Targets & Peak Sales Bounds (e.g., 'peak revenue potential >$10B', 'over 90 countries') — Excluded per Step 5 rule prohibiting bound/approximate numbers ('>', '<', '~', 'over', 'up to')
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Adjusted Free Cash Flow (Non-IFRS) › Acquisition of Intangible Assets (Cash Outflow)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Adjusted Net Debt to Adjusted EBITDA Leverage Ratio › Adjusted Cash and Cash Equivalents (Excluding Third-Party Vaccine Cash)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Capital Expenditures — Total Additions to PP&E and Intangible Assets (Data Book)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Capital Expenditures — Total Additions to PP&E and Intangible Assets (Data Book) › Capital Expenditures — Additions to Intangible Assets
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Capital Expenditures — Total Additions to PP&E and Intangible Assets (Data Book) › Capital Expenditures — Additions to Tangible Assets (PP&E)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Core Operating Profit (Non-IFRS) › Core Share of Profit/Loss of Investments Accounted for Using the Equity Method › Core Share of Profit/Loss of Investments Accounted for Using the Equity Method — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Amortization Associated with Products (Cash Flow Schedule)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Amortization Excluding Intangible Assets Associated with Products
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Amortization of Intangible Assets — Total
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Combined Amortization and Impairment Losses on Product Intangible Assets
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Depreciation and Amortization Excluding Intangible Assets Associated with Products
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Depreciation of Tangible Assets (PP&E)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Impairment Losses on Intangible Assets Associated with Products (Cash Flow Schedule)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Depreciation and Amortization — Total Consolidated D&A (Data Book) › Impairment Losses — Total (Cash Flow Schedule)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Basic EPS (IFRS) › Reported Basic EPS (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Basic EPS (IFRS) › Reported Basic EPS (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Impairment Losses on Intangible Assets Associated with Products (IFRS)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Impairment Losses on Intangible Assets Associated with Products (IFRS) › Reported Impairment Losses on Intangible Assets Associated with Products (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Impairment Losses on Intangible Assets Associated with Products (IFRS) › Reported Impairment Losses on Intangible Assets Associated with Products (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Income Tax Expense (IFRS) › Reported Income Tax Expense (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Income Tax Expense (IFRS) › Reported Income Tax Expense (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Net Profit Attributable to Owners of the Company (IFRS) › Reported Net Profit Attributable to Owners of the Company (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Net Profit Attributable to Owners of the Company (IFRS) › Reported Net Profit Attributable to Owners of the Company (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Net Profit for the Period (IFRS) › Reported Net Profit for the Period (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Net Profit for the Period (IFRS) › Reported Net Profit for the Period (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Operating Profit (IFRS Quarterly & Annual) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Profit Before Tax (IFRS)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Profit Before Tax (IFRS) › Reported Profit Before Tax (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Profit Before Tax (IFRS) › Reported Profit Before Tax (IFRS) — YoY Change (CER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Share of Profit/Loss of Equity Method Investments (IFRS) › Reported Share of Profit/Loss of Equity Method Investments (IFRS) — YoY Change (AER %)
- Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance › Reported Operating Profit (IFRS Quarterly & Annual) › Reported Share of Profit/Loss of Equity Method Investments (IFRS) › Reported Share of Profit/Loss of Equity Method Investments (IFRS) — YoY Change (CER %)
- Geographic Revenue Breakdown, Overseas Share & Revenue by Type (IFRS Note 4) › Total Consolidated Revenue (Regional Summary) › Europe and Canada (EUCAN) Revenue › Of Which: Canada & Other EUCAN Revenue › Of Which: Canada & Other EUCAN Revenue — YoY Change (Actual Exchange Rate / AER %)
- Geographic Revenue Breakdown, Overseas Share & Revenue by Type (IFRS Note 4) › Total Consolidated Revenue (Regional Summary) › Europe and Canada (EUCAN) Revenue › Of Which: Canada & Other EUCAN Revenue › Of Which: Canada & Other EUCAN Revenue — YoY Change (Constant Exchange Rate / CER %)
- Geographic Revenue Breakdown, Overseas Share & Revenue by Type (IFRS Note 4) › Total Consolidated Revenue (Regional Summary) › Europe and Canada (EUCAN) Revenue › Of Which: Europe Revenue › Of Which: Europe Revenue — YoY Change (Actual Exchange Rate / AER %)
- Geographic Revenue Breakdown, Overseas Share & Revenue by Type (IFRS Note 4) › Total Consolidated Revenue (Regional Summary) › Europe and Canada (EUCAN) Revenue › Of Which: Europe Revenue › Of Which: Europe Revenue — YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Europe and Canada Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Full-Year Management Forecast Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Full-Year Management Forecast Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Growth and Emerging Markets Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Japan Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) › ALOFISEL (Darvadstrocel — Complex Perianal Fistulas) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — Full-Year Management Forecast Revenue › PENTASA (Mesalamine) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — Full-Year Management Forecast Revenue › PENTASA (Mesalamine) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › PENTASA (Mesalamine) › PENTASA (Mesalamine) — U.S. Revenue › PENTASA (Mesalamine) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) — Full-Year Management Forecast Revenue › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Gastroenterology (GI) Business Area Total Revenue › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) — Full-Year Management Forecast Revenue › RESOLOR / MOTEGRITY (Prucalopride — Chronic Idiopathic Constipation) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ADDERALL XR (Mixed Amphetamine Salts Extended-Release — ADHD) › ADDERALL XR (Mixed Amphetamine Salts Extended-Release — ADHD) — Growth and Emerging Markets Revenue › ADDERALL XR (Mixed Amphetamine Salts Extended-Release — ADHD) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Europe and Canada Revenue › ROZEREM (Ramelteon — Insomnia) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Full-Year Management Forecast Revenue › ROZEREM (Ramelteon — Insomnia) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Full-Year Management Forecast Revenue › ROZEREM (Ramelteon — Insomnia) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Growth and Emerging Markets Revenue › ROZEREM (Ramelteon — Insomnia) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Japan Revenue › ROZEREM (Ramelteon — Insomnia) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › ROZEREM (Ramelteon — Insomnia) › ROZEREM (Ramelteon — Insomnia) — U.S. Revenue › ROZEREM (Ramelteon — Insomnia) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Neuroscience Business Area Total Revenue › TRINTELLIX (Vortioxetine — Major Depressive Disorder) › TRINTELLIX (Vortioxetine — Major Depressive Disorder) — Europe and Canada Revenue › TRINTELLIX (Vortioxetine — Major Depressive Disorder) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Europe and Canada Revenue › EXKIVITY (Mobocertinib) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Growth and Emerging Markets Revenue › EXKIVITY (Mobocertinib) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › EXKIVITY (Mobocertinib) › EXKIVITY (Mobocertinib) — U.S. Revenue › EXKIVITY (Mobocertinib) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › ICLUSIG (Ponatinib — CML & Ph+ ALL) › ICLUSIG (Ponatinib — CML & Ph+ ALL) — Full-Year Management Forecast Revenue › ICLUSIG (Ponatinib — CML & Ph+ ALL) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › NINLARO (Ixazomib — Oral Proteasome Inhibitor for Multiple Myeloma) › NINLARO (Ixazomib — Oral Proteasome Inhibitor for Multiple Myeloma) — Full-Year Management Forecast Revenue › NINLARO (Ixazomib — Oral Proteasome Inhibitor for Multiple Myeloma) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — Full-Year Management Forecast Revenue › VELCADE (Bortezomib — Multiple Myeloma) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — Full-Year Management Forecast Revenue › VELCADE (Bortezomib — Multiple Myeloma) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — International (Ex-U.S.) Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — International (Ex-U.S.) Revenue › VELCADE (Bortezomib — Multiple Myeloma) — International (Ex-U.S.) Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Oncology Business Area Total Revenue › VELCADE (Bortezomib — Multiple Myeloma) › VELCADE (Bortezomib — Multiple Myeloma) — U.S. Revenue › VELCADE (Bortezomib — Multiple Myeloma) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Europe and Canada Revenue › ACTOVEGIN — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Full-Year Management Forecast Revenue › ACTOVEGIN — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Full-Year Management Forecast Revenue › ACTOVEGIN — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Growth and Emerging Markets Revenue › ACTOVEGIN — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › ACTOVEGIN › ACTOVEGIN — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Full-Year Management Forecast Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Full-Year Management Forecast Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Japan Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Other Business Areas & Established Products Total Revenue › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) › LOTRIGA (Omega-3-Acid Ethyl Esters 90 — Hyperlipidemia) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › HEMOFIL / IMMUNATE / IMMUNINE (Plasma-Derived Coagulation Factors) › HEMOFIL / IMMUNATE / IMMUNINE (Plasma-Derived Coagulation Factors) — Full-Year Management Forecast Revenue › HEMOFIL / IMMUNATE / IMMUNINE (Plasma-Derived Coagulation Factors) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Europe and Canada Revenue › Other PDT Coagulation Products (Historical) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Full-Year Management Forecast Revenue › Other PDT Coagulation Products (Historical) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Full-Year Management Forecast Revenue › Other PDT Coagulation Products (Historical) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Growth and Emerging Markets Revenue › Other PDT Coagulation Products (Historical) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Japan Revenue › Other PDT Coagulation Products (Historical) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue › Other PDT Coagulation Products (Historical) › Other PDT Coagulation Products (Historical) — U.S. Revenue › Other PDT Coagulation Products (Historical) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › ADVATE (Antihemophilic Factor Recombinant — Hemophilia A) › ADVATE (Antihemophilic Factor Recombinant — Hemophilia A) — Full-Year Management Forecast Revenue › ADVATE (Antihemophilic Factor Recombinant — Hemophilia A) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › ADZYNMA (ADAMTS13, Recombinant-krhn — Congenital TTP) › ADZYNMA (ADAMTS13, Recombinant-krhn — Congenital TTP) — Growth and Emerging Markets Revenue › ADZYNMA (ADAMTS13, Recombinant-krhn — Congenital TTP) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › ELAPRASE (Idursulfase — Hunter Syndrome / MPS II) › ELAPRASE (Idursulfase — Hunter Syndrome / MPS II) — Full-Year Management Forecast Revenue › ELAPRASE (Idursulfase — Hunter Syndrome / MPS II) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › FIRAZYR (Icatibant — Acute Hereditary Angioedema) › FIRAZYR (Icatibant — Acute Hereditary Angioedema) — Full-Year Management Forecast Revenue › FIRAZYR (Icatibant — Acute Hereditary Angioedema) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Europe and Canada Revenue › Other Rare Genetics Products (Historical) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Growth and Emerging Markets Revenue › Other Rare Genetics Products (Historical) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Genetics Products (Historical) › Other Rare Genetics Products (Historical) — U.S. Revenue › Other Rare Genetics Products (Historical) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Europe and Canada Revenue › Other Rare Hematology Products (Historical) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Growth and Emerging Markets Revenue › Other Rare Hematology Products (Historical) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Japan Revenue › Other Rare Hematology Products (Historical) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Other Rare Hematology Products (Historical) › Other Rare Hematology Products (Historical) — U.S. Revenue › Other Rare Hematology Products (Historical) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Europe and Canada Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Full-Year Management Forecast Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Full-Year Management Forecast Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) — Full-Year Forecast YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Full-Year Management Forecast Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) — Full-Year Forecast YoY Change (CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Growth and Emerging Markets Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) › RECOMBINATE (Antihemophilic Factor Recombinant) — U.S. Revenue › RECOMBINATE (Antihemophilic Factor Recombinant) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Europe and Canada Revenue › Rare Genetics and Other Sub-Total (Historical Classification) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue › Rare Genetics and Other Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Japan Revenue › Rare Genetics and Other Sub-Total (Historical Classification) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Genetics and Other Sub-Total (Historical Classification) › Rare Genetics and Other Sub-Total (Historical Classification) — U.S. Revenue › Rare Genetics and Other Sub-Total (Historical Classification) — U.S. Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Europe and Canada Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Europe and Canada Revenue › Rare Hematology Sub-Total (Historical Classification) — Europe and Canada Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue › Rare Hematology Sub-Total (Historical Classification) — Growth and Emerging Markets Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Japan Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Japan Revenue › Rare Hematology Sub-Total (Historical Classification) — Japan Revenue YoY Change (AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Total Revenue YoY Change (Actual Exchange Rate / AER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — Total Revenue YoY Change (Constant Exchange Rate / CER %)
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — U.S. Revenue
- Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts) › Rare Diseases Business Area Total Revenue › Rare Hematology Sub-Total (Historical Classification) › Rare Hematology Sub-Total (Historical Classification) — U.S. Revenue › Rare Hematology Sub-Total (Historical Classification) — U.S. Revenue YoY Change (AER %)
- R&D Clinical Pipeline by Phase, BioLife Plasma Collection Network & Global Manufacturing Facilities › Phase 1 Clinical Pipeline — Lifecycle Management (LCM) Programs
- Unconsolidated Parent Company (Takeda Pharmaceutical Company Limited, J-GAAP) & Subsidiary Transactions › Subsidiary Transaction — Takeda Pharmaceuticals International AG (Product Sales)
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Key Business Areas & Product Portfolio Revenue (Quarterly & Annual, Regional Breakdown, CER Growth & Forecasts)
- Gastroenterology (GI) Business Area Total Revenue22 kỳ
- Rare Diseases Business Area Total Revenue22 kỳ
- Plasma-Derived Therapies (PDT) Immunology Business Area Total Revenue22 kỳ
- Oncology Business Area Total Revenue22 kỳ
- Vaccines Business Area Total Revenue14 kỳ
- Neuroscience Business Area Total Revenue22 kỳ
- Other Business Areas & Established Products Total Revenue22 kỳ
Geographic Revenue Breakdown, Overseas Share & Revenue by Type (IFRS Note 4)
R&D Clinical Pipeline by Phase, BioLife Plasma Collection Network & Global Manufacturing Facilities
- Phase 1 Clinical Pipeline — New Molecular Entities (NMEs)14 kỳ
- Phase 2 Clinical Pipeline — New Molecular Entities (NMEs)14 kỳ
- Phase 2 Clinical Pipeline — Lifecycle Management (LCM) Programs2 kỳ
- Phase 3 Clinical Pipeline — New Molecular Entities (NMEs)14 kỳ
- Phase 3 Clinical Pipeline — Lifecycle Management (LCM) Programs14 kỳ
- Registration / Filed Stage Pipeline — New Molecular Entities (NMEs)11 kỳ
- Registration / Filed Stage Pipeline — Lifecycle Management (LCM) Programs14 kỳ
- Product Innovation — Vitality Index (% of Gross Revenue from Products Launched in Past 5 Years)5 kỳ
- Consolidated R&D Expense Ratio to Revenue (%)7 kỳ
- Consolidated R&D Expenses (AGM Business Report)7 kỳ
- BioLife Plasma Services — Total Global Plasma Collection Centers (U.S. & Europe)5 kỳ
- Major Facility Land Area — Osaka Head Office (Chuo-ku, Osaka, Japan)4 kỳ
- Major Facility Land Area — Hikari Plant (Hikari, Yamaguchi, Japan)4 kỳ
- Major Facility Land Area — Yodogawa Plant (Yodogawa-ku, Osaka, Japan)2 kỳ
- Major Facility Land Area — Baxalta US Inc. Plasma Manufacturing (Covington, GA, U.S.)4 kỳ
- Major Facility Land Area — Shire Human Genetic Therapies Campus (Lexington, MA, U.S.)4 kỳ
- Major Facility Land Area — BioLife Plasma Services LP (Bannockburn, IL & U.S. Centers)4 kỳ
- Major Facility Land Area — Takeda Manufacturing Austria AG (Vienna, Austria)4 kỳ
- Major Facility Land Area — Baxalta Belgium Manufacturing SA (Lessines, Belgium)4 kỳ
- Major Facility Land Area — Baxalta Manufacturing S.à r.l. (Neuchatel, Switzerland)4 kỳ
Core Operations (Non-IFRS), Reported-to-Core Reconciliations, Cash Flow, Leverage & Full-Year Guidance
- Core Operating Profit (Non-IFRS)22 kỳ
- Reported Operating Profit (IFRS Quarterly & Annual)5 kỳ
- Reported-to-Core Operating Profit Adjustment — Amortization of Product Intangible Assets5 kỳ
- Reported-to-Core Operating Profit Adjustment — Impairment of Product Intangible Assets5 kỳ
- Reported-to-Core Operating Profit Adjustment — Other Operating Income/Expenses & Purchase Accounting5 kỳ
- Reported-to-Core Net Profit Adjustment — Amortization of Product Intangible Assets (Pre-Tax)22 kỳ
- Reported-to-Core Net Profit Adjustment — Impairment of Product Intangible Assets (Pre-Tax)21 kỳ
- Reported-to-Core Net Profit Adjustment — Other Operating & Non-Operating Non-Core Items22 kỳ
- Net Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1)18 kỳ
- Free Cash Flow (IFRS Operating Cash Flow Less PP&E Acquisition)18 kỳ
- Adjusted Free Cash Flow (Non-IFRS)14 kỳ
- Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×)11 kỳ
- Dividends Paid (Cash Outflow — Exhibit 99.1)18 kỳ
- Interest Paid (Cash Outflow — Exhibit 99.1)18 kỳ
- Period-End Total Consolidated Assets (Kessan Tanshin)15 kỳ
- Period-End Total Consolidated Equity (Kessan Tanshin)15 kỳ
- Period-End Equity Attributable to Owners of the Parent (Kessan Tanshin)15 kỳ
- Period-End Equity Attributable to Owners to Total Assets Ratio (%)15 kỳ
- Period-End Book Value per Share (Equity Attributable to Owners per Share)15 kỳ
- Period-End Total Shares Issued (Including Treasury Shares)15 kỳ
- Period-End Treasury Shares Held15 kỳ
- Annual Dividend per Share15 kỳ
- Full-Year Guidance — Consolidated Revenue (IFRS)15 kỳ
- Full-Year Guidance — Consolidated Operating Profit (IFRS)15 kỳ
- Full-Year Guidance — Consolidated Profit Before Tax (IFRS)15 kỳ
- Full-Year Guidance — Net Profit Attributable to Owners (IFRS)15 kỳ
- Full-Year Guidance — Reported Basic EPS (IFRS)15 kỳ
Exchange Rate Assumptions & Currency Sensitivity (USD, EUR, RUB, CNY, BRL)
- U.S. Dollar (USD/JPY) — Actual Period-to-Date Average Exchange Rate22 kỳ
- Euro (EUR/JPY) — Actual Period-to-Date Average Exchange Rate22 kỳ
- Russian Ruble (RUB/JPY) — Actual Period-to-Date Average Exchange Rate22 kỳ
- Chinese Yuan (CNY/JPY) — Actual Period-to-Date Average Exchange Rate22 kỳ
- Brazilian Real (BRL/JPY) — Actual Period-to-Date Average Exchange Rate22 kỳ
Unconsolidated Parent Company (Takeda Pharmaceutical Company Limited, J-GAAP) & Subsidiary Transactions
- Unconsolidated Parent (J-GAAP) — Net Sales (Exact)5 kỳ
- Unconsolidated Parent (J-GAAP) — Operating Income (Exact)5 kỳ
- Unconsolidated Parent (J-GAAP) — Ordinary Income (Exact)5 kỳ
- Unconsolidated Parent (J-GAAP) — Net Income (Exact)5 kỳ
- Unconsolidated Parent (J-GAAP) — Total Assets (Exact)5 kỳ
- Unconsolidated Parent — Intercompany Operating Sales to Subsidiaries & Affiliates3 kỳ
- Subsidiary Transaction — Takeda Development Center Americas, Inc. (R&D Outsourcing Payments)3 kỳ
- Subsidiary Transaction — Takeda Pharmaceuticals International AG (Royalty Receipts)3 kỳ
- Principal Bank Borrowings — The Norinchukin Bank4 kỳ
- Principal Bank Borrowings — Sumitomo Mitsui Trust Bank, Limited4 kỳ
- Principal Bank Borrowings — Shinkin Central Bank4 kỳ
- Unconsolidated Parent Company (Japan) — Permanent Employees4 kỳ
Workforce Headcount, Diversity, Turnover, Occupational Safety, Environmental Footprint & Governance
- Total Consolidated Employees (Full-Time Equivalent / FTE — Form 20-F)6 kỳ
- Global Employee Turnover Rate — Total4 kỳ
- Workforce Diversity — Women in Management Positions (%)4 kỳ
- Occupational Health & Safety — Total Recordable Incident Rate (TRIR per 200,000 Hours)3 kỳ
- GHG Emissions — Total Scope 1, 2 & 3 Emissions (Market-Based)3 kỳ
- Energy Consumption — Total Energy Consumed (Scopes 1 and 2)3 kỳ
- Water Stewardship — Total Freshwater Withdrawal3 kỳ
- Waste Management — Total Waste Generated3 kỳ
- Access to Medicines — Patients Enrolled in Charitable Access Programs5 kỳ
- Access to Medicines — Countries with Access to Medicines Programs5 kỳ
- Product Quality — FDA Class I Product Recalls (U.S.)5 kỳ
- Product Quality — FDA Class II Product Recalls (U.S.)5 kỳ
- Supply Chain Sustainability — PSCI On-Site Supplier Audits Conducted5 kỳ
- Supply Chain Sustainability — Suppliers with EcoVadis Desktop Audits Conducted4 kỳ
- Ethics & Compliance — Global Employees Trained on Anti-Corruption Policies (%)5 kỳ
- Ethics & Compliance — Global Employees Trained on Takeda Code of Conduct (%)5 kỳ
- Ethics & Compliance — Confirmed Discrimination and Harassment Incidents5 kỳ
- Corporate Citizenship — Cumulative Global CSR Program Commitments Since 20165 kỳ
- Public Policy — Corporate Lobbying Expenditures (U.S., EU, Japan)5 kỳ
- Public Policy — Political Contributions5 kỳ
- Public Policy — Trade Association Memberships Spend5 kỳ
External Macro & Pharmaceutical Industry Benchmarks (FRED)
- Spot Exchange Rate — Japanese Yen per U.S. Dollar (FRED DEXJPUS)130 kỳ
- Spot Exchange Rate — U.S. Dollars per Euro (FRED DEXUSEU)130 kỳ
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (FRED PCU325412325412)43 kỳ
- U.S. Consumer Price Index — Medical Care Commodities (FRED CUSR0000SAM1)42 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted (FRED MRTSSM44611USS)10 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted (FRED MRTSSM44611USN)10 kỳ
- U.S. Personal Consumption Expenditures — Health Care Services, SAAR (FRED DHLCRC1M027SBEA)43 kỳ
Consolidated Financial Statements & Segment Context (Database)
- DB Consolidated Revenue (IFRS Annual — Form 20-F)10 kỳ
- DB Total Consolidated Assets (IFRS Annual — Form 20-F)9 kỳ
- DB Operating Cash Flow (IFRS Annual — Form 20-F)10 kỳ
- DB Geographic Segment Revenue — United States (Form 20-F Note 4)10 kỳ
- DB Product Segment Revenue — Total Pharmaceutical Products (Form 20-F Note 4)10 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Takeda Pharmaceutical
- Takeda ESG Metrics Data Book (esg_metrics_en.pdf) ↗
- xlsx_fy2026q4 ↗
- SEC EDGAR Filing (tak-20260331.htm) ↗
- SEC EDGAR Filing (form6k-1_102926.htm) ↗
- xlsx_fy2027q2 ↗
- SEC EDGAR Filing (noticeofconvocationofthe.htm) ↗
- Takeda Investor Relations Disclosure (qr2025_q4_p01_en_20260605.pdf) ↗
- SEC EDGAR Filing (form6k_051326.htm) ↗
- Takeda Investor Relations Disclosure (qr2026_q2_Pipeline_table_en.pdf) ↗
- SEC EDGAR Filing (exhibit991_102926.htm) ↗
- SEC EDGAR Filing (exhibit991_051326.htm) ↗
- Takeda Investor Relations Disclosure (qr2026_q2_p01_en.pdf) ↗
See a number that looks wrong?